Valneva SE

Valneva to Present at the Cowen 43rd Annual Healthcare Conference

01 Mar 2023 11:45:00 By Nasdaq GlobeNewswire

FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review

20 Feb 2023 01:00:00 By Nasdaq GlobeNewswire

Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

17 Feb 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Full Year 2022 Revenue and Cash, Provides First 2023 Guidance

16 Feb 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

14 Feb 2023 01:00:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights - January 31, 2023

03 Feb 2023 12:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: Status on December 31, 2022 (corrected data) and January 4, 2023

19 Jan 2023 12:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: December 31, 2022

05 Jan 2023 12:00:00 By Nasdaq GlobeNewswire

Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine

30 Dec 2022 12:30:00 By Nasdaq GlobeNewswire

Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate

23 Dec 2022 01:00:00 By Nasdaq GlobeNewswire

Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum

21 Dec 2022 11:45:00 By Nasdaq GlobeNewswire

Valneva Hosts Investor Day in New York City

06 Dec 2022 01:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: November 30, 2022

05 Dec 2022 12:00:00 By Nasdaq GlobeNewswire

Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate

05 Dec 2022 01:00:00 By Nasdaq GlobeNewswire

Valneva to Host Investor Day in New York City

29 Nov 2022 12:00:00 By Nasdaq GlobeNewswire

Valneva Appoints Dipal Patel as Chief Commercial Officer

17 Nov 2022 01:00:00 By Nasdaq GlobeNewswire

Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates

10 Nov 2022 01:00:00 By Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference

07 Nov 2022 11:45:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: October 31, 2022

04 Nov 2022 13:00:00 By Nasdaq GlobeNewswire

Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientific Conferences

10 Oct 2022 01:00:00 By Nasdaq GlobeNewswire